Averin Capital Acquisition
- Company typePrivate
- Founded2026
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Averin Capital Acquisition firmographics
Firmographics- Name
- Averin Capital Acquisition
- Legal name
- Averin Capital, LLC
- Website
- https://averincapital.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Averin Capital Acquisition industry classification
Industry- Product category
- Venture Capital & Private Equity
- NAICS
- Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro industry
- Capital Markets Advisory (IPO Readiness, SPAC, ECM/DCM Advisory)Business & Public Services/Professional Services (Legal, Accounting, Consulting)/M&A, Transaction & Restructuring AdvisoryCapital Raising Advisory (Equity & Equity-Linked)Financial & Insurance/Financial Advisory, Brokerage & Intermediation/M&A Advisory & Corporate FinanceCorporate M&A / Venture Build-to-Buy Programs (Acqui-hire, option-to-acquire)
Keywords
Where Averin Capital Acquisition is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Averin Capital Acquisition business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- SPAC Proceeds: As a Special Purpose Acquisition Company (SPAC), the company raised $250 million in its IPO to acquire one or more businesses in the technology and health sectors. Proceeds are held in a U.S.-based trust account managed by Continental Stock Transfer & Trust Company pending business combination.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Averin Capital Acquisition product offering
Product offeringCore offering
Averin Capital Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) that raised $250 million in its February 2026 IPO on Nasdaq to acquire one or more businesses at the intersection of technology and health. The firm is operated by an investment team with deep operator experience founding, building, and scaling more than 30 companies. Proceeds are held in a U.S.-based trust account pending a business combination with a target company.
Product overview
Averin Capital is a venture capital and investment advisory firm that invests at the intersection of technology and health. The firm provides capital and operational expertise to visionary teams scaling healthcare companies. Averin's portfolio spans five primary investments: Biolinq (wearable biosensing for metabolic health), CandidPro (AI-assisted dental aligners and monitoring), Freenome (multiomics liquid biopsy for cancer detection), Hologen AI (Large Medicine Models for clinical trial optimization), and Pine Park Health (senior primary care delivery). Rather than offering a unified software platform, Averin functions as an operational partner to its portfolio companies, offering strategic guidance across technology and health sectors.
Differentiator
Problem solved
Functional benefit
Products and services
- SPAC IPO Units (Nasdaq: ACAAU) Public investment units issued by Averin Capital Acquisition Corp. as part of its initial public offering, giving investors exposure to a future business combination in the technology and health sectors.
- Venture Capital & Investment Advisory Services
Quantifiable outcome
- 22 companies worth over $1B impacted by the Averin team
- +1 more outcomes
Companies that use Averin Capital Acquisition
Customer profileSegments1 record
Ideal customer profiles2 records
Averin Capital Acquisition technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Averin Capital Acquisition partnerships and signals
Strategic signalScale indicators4 records
Recent moves7 records
Expansion highlights4 records
Averin Capital Acquisition competitors and assessment
Company assessmentBroad incumbents
- Andreessen Horowitz Bio Fund: Healthcare and life-sciences-focused venture franchise where Averin Partner Jeffrey Low previously worked. Both firms invest at the intersection of technology and biology with thesis-driven, operator-partnered models.
- Novo Holdings: Healthcare and life-sciences investor where Averin Partner Jeffrey Low previously led strategy. Comparable in sector mandate and long-duration capital approach to health-tech investments.
- Vista Equity Partners: Large technology-focused private equity firm that acquired TripleLift (co-founded by Eric Berry) for over $1.4B. Comparable as a scaled technology investor with proven exit outcomes for Averin leadership alumni.
- Roivant Sciences: Healthcare technology platform where Averin Partner Tristan Hunt previously served as COO of Roivant Health. Comparable in combining technology with biopharma/healthcare delivery and operating at scale across multiple subsidiaries.
- Mubadala Capital: Global sovereign-affiliated investor that co-led Salma Health's Series A alongside ARCH and Averin. Comparable as a large-scale, multi-stage investor in technology and healthcare ventures.
- ARCH Venture Partners: Premier healthcare and technology venture firm and co-lead of the Salma Health Series A in which Averin participated. Directly comparable in sector focus and stage profile of investments.
- OpenView Venture Partners: Expansion-stage venture firm where Averin Partner & COO Alex Lau spent over a decade leading firm operations and scaling AUM. Directly comparable in operating discipline and growth-stage investment focus.
Direct peers
- Social Capital Hedosophia (Chamath Palihapitiya): Pioneer of technology-focused SPAC vehicles; the SPAC sponsor/operator-led public acquisition model most resembles Averin's structure. Both teams operate as branded operators raising public capital to acquire private growth companies.
- Flagship Pioneering: Flagship Pioneering is a venture creation firm where David Berry previously served as General Partner. Both firms operate at the intersection of technology and life sciences, build and incubate companies, and pursue outsized science-driven outcomes — making Flagship the closest comparable operating model.
Regional players
- Altimar Capital Acquisition Corp. Health/technology-focused SPAC sponsor with a similar blank-check structure targeting consumer, healthcare and technology businesses. Closest SPAC-form direct comparable focused on the same target sectors.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Averin Capital Acquisition social profiles
Digital presenceAverin Capital Acquisition financial estimates
Financial estimateRevenue estimate
Valuation estimate
Averin Capital Acquisition leadership team
Management profileNumber of profiles
Profiles8 records
Averin Capital Acquisition funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Averin Capital Acquisition M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Averin Capital Acquisition
What does Averin Capital Acquisition do?
Averin Capital Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) that raised $250 million in its February 2026 IPO on Nasdaq to acquire one or more businesses at the intersection of technology and health. The firm is operated by an investment team with deep operator experience founding, building, and scaling more than 30 companies. Proceeds are held in a U.S.-based trust account pending a business combination with a target company.
Is Averin Capital Acquisition a public or private company?
Averin Capital Acquisition is a private company. It is classified as public and is currently operating.
When was Averin Capital Acquisition founded?
Averin Capital Acquisition was founded in 2026. It employs 1 to 10 people.
Where is Averin Capital Acquisition based?
Averin Capital Acquisition is headquartered in New York, United States, in the North America region.
How does Averin Capital Acquisition make money?
One revenue line is on record: SPAC Proceeds.
Who are Averin Capital Acquisition's main competitors?
Broad incumbents on record are Andreessen Horowitz Bio Fund, Novo Holdings, Vista Equity Partners, Roivant Sciences, Mubadala Capital, ARCH Venture Partners and OpenView Venture Partners. Direct peers are Social Capital Hedosophia (Chamath Palihapitiya) and Flagship Pioneering. Altimar Capital Acquisition Corp. is listed as a regional player.
Does Averin Capital Acquisition have an API?
No public API is recorded for Averin Capital Acquisition.
What industry is Averin Capital Acquisition in?
Averin Capital Acquisition's product category is Venture Capital & Private Equity. Its primary akta.pro industry code is BPAHAOAL, Capital Markets Advisory (IPO Readiness, SPAC, ECM/DCM Advisory), with a secondary code of FSAEAGAC, Capital Raising Advisory (Equity & Equity-Linked). Its NAICS code is 523 and its SIC code is 6211.